Sign in
TNFA Stock Price, Chart, Stats & News
TNF Pharmaceuticals, Inc.
Save
9.18M
Market cap
–
Current P/E
–
Forward P/E
TNFA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.32% |
ROE | -48.34% |
D/E | – |
Interest coverage ratio | – |
TNFA valuation
P/E | – |
P/S | – |
P/B | 0.07x |
P/CF | -0.09x |
P/FCF | -1.01x |
P/OCF | -0.09x |
PEG | -0.00x |
EV multiple | -1.13x |
About
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials. This platform functions by modulating the immune system to regulate TNF-alpha—a key driver of chronic inflammation—and other pro-inflammatory cytokines.
Similar securities
Based on sector and market capitalization
Report issue